Oxazolidinone Liposome Compositions with Improved Storage Stability
Summary
The USPTO has published a new patent application from Akagera Medicines, Inc. detailing oxazolidinone liposome compositions designed for improved storage stability. The application, filed on December 2, 2025, describes methods for manufacturing and using these compositions.
What changed
This document is a publication of a new patent application (US20260083674A1) filed by Akagera Medicines, Inc. The application describes novel liposomal compositions containing oxazolidinone compounds, focusing on enhanced storage stability and reduced component degradation. It also covers related manufacturing and usage methods.
As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signifies potential future intellectual property developments in the pharmaceutical sector, particularly concerning drug formulation and stability. Companies in this space should be aware of this filing as it may impact their own research and development or patent strategies.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
OXAZOLIDINONE LIPOSOME COMPOSITIONS
Application US20260083674A1 Kind: A1 Mar 26, 2026
Assignee
Akagera Medicines, Inc.
Inventors
Dmitri B. Kirpotin, Alexander Koshkaryev, Charles O. Noble, Daryl C. Drummond
Abstract
Aspects of the disclosure relate to various liposomal compositions of oxazolidinone compounds, and related methods of manufacturing and using the oxazolidinone liposome compositions. In some embodiments, the liposome compositions have improved storage stability with regard to component degradation.
CPC Classifications
A61K 9/1271 A61K 9/1277 A61K 31/4439 A61K 47/02 A61K 47/183 A61P 31/04 A61P 31/06
Filing Date
2025-12-02
Application No.
19405695
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.